San Diego—May 19, 2025–Rady Children’s Institute for Genomic Medicine (RCIGM®) today announced that Alexion, AstraZeneca Rare Disease has signed on as the first Platinum member of the Begin ...

Please provide your email address to receive an email ... Disclosures: Lee reports consulting for Alexion, Amgen/Horizon, AstraZeneca, Bristol Myers Squibb, Catalyst, Dompe, Etyreal, Stoke ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a $753 million hit for abandoning one of the drugs from that ...

Please provide your email address to receive an email when new articles are posted on . In an early study, a gene-editing therapy drastically reduced levels of transthyretin, the protein that ...

Voydeya was developed within Alexion, AstraZeneca Rare Disease, the pharma giant’s rare disease division created from the 2021 acquisition of Alexion Pharmaceuticals for $39 billion. As a ...

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. AstraZeneca on Wednesday ...

Alexion, AstraZeneca Rare Disease, a subsidiary of AstraZeneca Plc, a leading pharmaceutical company, has entered into a definitive agreement to acquire and license certain early-stage medicines from ...

AstraZeneca reported higher-than-expected revenue on strong sales of its cancer drugs. Alexion, AstraZeneca's rare disease arm, said it will buy Pfizer's portfolio of pre-clinical gene therapies ...

LONDON: British drugmaker AstraZeneca on Thursday posted surging annual net profit, boosted by cancer treatments and the integration of biotech unit Alexion following a blockbuster takeover.

LogicBio Therapeutics a Massachusetts-based, clinical-stage genomic medicine company, announced on Monday that the company is being acquired by Alexion, AstraZeneca Rare Disease. Under the terms ...

AstraZeneca's Rare Disease group, Alexion, is investing €65m in new and enhanced capabilities across its sites in College Park in Blanchardstown and Monksland Industrial Park in Athlone.

Last July, AstraZeneca announced a $39 billion acquisition of Alexion, immediately giving the U.K. pharma's top line a $6 billion bump thanks to Alexion’s blockbuster C5 inhibitor franchises ...